Anavar 50 mg 50 tabs Saxon Pharma USA
$129.00
Product Short Description
Anavar 50 mg 50 Tablets Saxon Pharma USA delivers oxandrolone (C19H30O3) at premium 50 mg strength representing 5-20× prescription dosing in a sealed 50-tablet bottle matching DEA Schedule III controlled substance standards. Domestic U.S. production eliminates customs exposure serving institutional performance distribution exclusively.
Product Overview
Saxon Pharma USA’s Anavar 50 mg formulation presents oxandrolone, the C2-oxa substituted DHT derivative exhibiting pharmaceutical-grade anabolic properties (~322-630 rating), in institutional 50 mg scored tablets identical to high-potency performance specifications. The 50-tablet tamper-evident configuration supports CIII-compliant catalog integration for advanced buyers managing structured DEA-regulated inventories across encrypted specialist platforms.
Domestic manufacturing through U.S. facilities maintains USP-equivalent morphology (white scored tablets, molecular weight 306.44) distinguishing legitimate Schedule III product from underground powder conversions prevalent in non-verified channels. This elevated dosage serves institutional resellers requiring Form 222 traceability rather than pharmaceutical crossover or recreational supplement positioning.
Anavar 50 mg targets verified CIII ecosystems exclusively, emphasizing commercial verification protocols without usage guidance, cycles, or outcome representations.
Brand & Manufacturer Information
Saxon Pharma USA produces Schedule III anabolics through domestic GMP facilities serving institutional performance resellers requiring controlled substance compliance. Anavar maintains catalog continuity alongside Saxon high-potency orals with consistent 50 mg tablet specifications enabling SKU differentiation from 10-25 mg variants while authenticating legitimate institutional supply.
U.S. warehousing supports DEA-compliant encrypted platforms confirming oxandrolone identity/potency distinguishing Saxon from international grey-market exposure.
Active Compound Information
Contains oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one), 17α-alkylated DHT featuring high anabolic:androgenic dissociation (~10:1) with no aromatization characteristic of C2-oxa substitution enabling oral bioavailability. DEA Schedule III (21 CFR 1308.13) classification reflects hepatotoxicity profile at performance escalation beyond prescription 2.5-10 mg Oxandrin.
50 mg strength positions institutional-grade while maintaining C17α-methylation preventing first-pass metabolism. WADA S1a prohibited; regulated across U.S. jurisdictions.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Anavar 50 mg 50 Tablets Saxon Pharma USA |
| Active Compound | Oxandrolone (C19H30O3) |
| Strength | 50 mg per scored tablet |
| Quantity | 50 tablets per bottle |
| Form | Oral scored tablets |
| Category | DEA Schedule III controlled substance |
| Packaging | Tamper-evident HDPE bottle |
| Label Elements | 50 mg declaration, CIII warnings, batch code |
Quality Control & Testing Standards
50 mg oxandrolone mandates USP potency assay (90-110% HPLC), forced degradation stability, and uniformity exceeding pharmaceutical monographs. Saxon batch documentation verifies C19H30O3 identity, content uniformity, and Schedule III-compliant excipients.
50-tablet institutional bottling prevents diversion; domestic warehousing maintains stability distinguishing legitimate product from underground alternatives.
Intended Use & Market Positioning
Serves CIII-licensed institutional performance researchers managing high-dosage DEA Schedule III inventories exclusively. 50 mg/50-tab excludes crossover positioning within premium domestic catalogs. No protocols represented.
Legal & Regulatory Disclaimer
Oxandrolone constitutes DEA Schedule III under 21 USC §812; non-medical distribution/possession violates Controlled Substances Act (5 years/$250,000 penalties). Buyer assumes Form 222/DEA licensing compliance; zero medical claims/protocols provided.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.